ストックスクリーナーアプリを入手
26.21
1.50%
0.3639
前日終値:
$25.85
開ける：
$25.85
24時間の取引高:
23.24M
Relative Volume:
0.63
時価総額：
$149.38B
収益：
$63.32B
当期純損益:
$7.52B
株価収益率:
20.10
EPS:
1.3043
ネットキャッシュフロー:
$9.48B
1週間 パフォーマンス:
+1.74%
1か月 パフォーマンス:
-2.06%
6か月 パフォーマンス:
+2.05%
1年 パフォーマンス:
+11.13%
1日の値動き範囲:
$25.85
$26.54
1週間の範囲:
$25.57
$26.54
52週間の値動き範囲:
$23.06
$28.75
Pfizer Inc Stock (PFE) Company Profile
Compare PFE vs LLY, JNJ, ABBV, MRK, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
26.21 | 147.33B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,085.38 | 949.47B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
231.86 | 554.09B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
214.81 | 376.54B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.78 | 295.69B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
187.01 | 290.30B | 60.48B | 10.40B | 8.05B | 3.3297 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-02 | アップグレード | Argus | Hold → Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Underperform |
| 2026-02-20 | 開始されました | Barclays | Underweight |
| 2026-02-12 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-02 | 再開されました | Citigroup | Neutral |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-25 | 再開されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | ダウングレード | Argus | Buy → Hold |
| 2024-02-23 | 開始されました | Guggenheim | Buy |
| 2024-01-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-10-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-17 | 繰り返されました | JP Morgan | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-06-29 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | ダウングレード | UBS | Buy → Neutral |
| 2023-01-17 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-12-13 | アップグレード | Goldman | Neutral → Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-01-05 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-20 | 繰り返されました | Cowen | Outperform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-13 | アップグレード | UBS | Neutral → Buy |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-05-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | アップグレード | DZ Bank | Hold → Buy |
| 2020-12-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 再開されました | Goldman | Neutral |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-10-12 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-16 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-27 | アップグレード | Standpoint Research | Hold → Buy |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-07-30 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 再開されました | Morgan Stanley | Overweight |
| 2019-02-20 | 再開されました | Citigroup | Neutral |
| 2019-01-31 | アップグレード | Argus | Hold → Buy |
| 2019-01-31 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | ダウングレード | UBS | Buy → Neutral |
| 2018-12-11 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-11-01 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
すべてを表示
Pfizer Inc (PFE) 最新ニュース
Pfizer to Webcast Healthcare Conference Discussion - geneonline.com
UBS maintains Pfizer stock rating ahead of cancer drug trial results - Investing.com
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference - Yahoo Finance Singapore
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure? - Yahoo Finance Singapore
BofA Raises Price Target on Pfizer (PFE) Following Strong Q1 Results - Insider Monkey
Pfizer (PFE.US) has received approval in China for a new formulation of its blockbuster anti-infective innovative drug, further enhancing the treatment regimen for invasive fungal diseases in children. - Moomoo
UBS Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27 - Moomoo
Pfizer Beats Q1 Estimates and Advances Its Pipeline. Here’s Whether It Is Worth Buying at $26 - TIKR.com
Pfizer's BRAFTOVI® Becomes First Pfizer Therapy to Receive Priority Access Under Ontario's FAST Program, Accelerating Treatment for Canadians with Metastatic Colorectal Cancer - PR Newswire Canada
Is Pfizer Inc. (PFE) One of the Best Medical Stocks to Invest in According to Billionaires? - Yahoo Finance
Citi Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $27 - Moomoo
Pfizer (PFE) Valuation Check After New HYMPAVZI Approval Vaccine Data And Oncology Collaboration - simplywall.st
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
How The Investment Narrative For Pfizer (PFE) Is Shifting On Pipeline Hopes And Revenue Risks - Yahoo Finance
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Research Rising: Recognizing Clinical Trials Day 2026 - Pfizer
Pfizer Inc. stock (US7170811035): Cancer focus and pipeline updates keep investors watching PFE - AD HOC NEWS
Pfizer's CEO uses AI to make his biggest calls — and 64% of CEOs agree, quietly shifting your portfolio - Yahoo Finance
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38% - The Globe and Mail
Pfizer, Inc. (PFE) Stock Analysis: Exploring a 12.69% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Pfizer stock (US7170811035): oncology collaboration and cautious recovery draw fresh attention - AD HOC NEWS
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript - GuruFocus
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns - Yahoo Finance UK
Pfizer Collaboration Targets Faster Cancer Trials While Shares Trade Below Value - simplywall.st
Pfizer’s SWOT analysis: stock navigates patent cliff with new drugs - Investing.com
Pfizer’s SWOT analysis: stock navigates patent cliff with new drugs By Investing.com - Investing.com UK
The Most Important Healthcare Stock You're Not Watching - Yahoo Finance
PFE Stock Quote Price and Forecast - CNN
Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study - TipRanks
Pfizer class action alleges website tracked users despite cookie opt-outs - Class Action Lawsuits
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned? - Yahoo Finance Singapore
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
TREM2 agonists detailed in Pfizer patent - BioWorld News
Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks - Yahoo Finance
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A EffortsReiterate Buy (NYSE:PFE) - Seeking Alpha
Kimberly-Clark (KMB) vs Pfizer (PFE): Defensive Dividend Showdown for 2026 - Gotrade
Pfizer wins Singapore trademark dispute with Merck over vaccine brand - The Straits Times
Pfizer Inc.: Target Price Consensus and Analysts Recommendations | PFE | US7170811035 - marketscreener.com
Pfizer Inc. stock (US7170811035): vaccine data and hemophilia approval put pharma giant back in focu - AD HOC NEWS
Pfizer Inc. Trade Ideas — BX:PFEUSD - TradingView
Goldman Sachs Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $26 - Moomoo
Building an AI-Fluent Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Building an AI-Literate Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Pfizer (PFE) Valuation Check After HYMPAVZI Expansion And Positive Pneumococcal Vaccine Data - Yahoo Finance
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and PfizerGlobal Forecast to 2030 and 2035 - Yahoo Finance UK
Comirnaty vaccine guide: how Pfizer's mRNA shot works - AD HOC NEWS
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Pfizer Inc (PFE) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.06%
大文字化:
|
ボリューム (24 時間):